The effect of a continuous infusion of human brain natriuretic peptide, 2 pmol:min − 1 :kg − 1 , during 60 min was studied in nine patients with congestive heart failure and in 10 healthy control subjects. Brain natriuretic peptide increased from 1.6 to 101 pmol/l in control subjects and from 25 to 173 pmol/l in congestive heart failure during infusion. Urinary sodium excretion increased significantly in both congestive heart failure (60 %) and control subjects (71 %), but the absolute increase was significantly lower in congestive heart failure (27 µmol/min) than in control subjects (190 µmol/min). Urinary flow rate did not change. The lithium clearance technique was used to evaluate the segmental tubular function ; the distal fractional reabsorption of sodium decreased significantly less in congestive heart failure (DFR Na : k0.8 %) than in control subjects (DFR Na : k3.7 %). Baseline values for glomerular filtration rate and renal plasma flow were reduced in congestive heart failure, but brain natriuretic peptide induced no significant changes between congestive heart failure and control subjects. Brain natriuretic peptide induced the same absolute increase in secondary messenger cGMP in plasma and urine in both patients and healthy subjects. It is concluded that the natriuretic response to brain natriuretic peptide infusion was impaired in patients with congestive heart failure compared with healthy subjects, and it is likely that the impaired natriuretic response was caused by a reduced responsiveness in the distal part of the nephron.
INTRODUCTION
Water-and sodium-retaining systems, such as the reninangiotensin-aldosterone system and arginine vasopressin, are activated in congestive heart failure (CHF) [1, 2] . In addition, both atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are increased in plasma [3, 4] , and the increase is correlated with the severity of cardiac dysfunction [5] [6] [7] . ANP and BNP are structurally similar, but BNP is mainly derived from the Yoshimura et al. [14] reported severe natriuretic and diuretic effects of BNP infusion, whereas Marcus et al. [15] found an approximate doubling of the natriuresis and a lesser effect on diuresis. Lainchbury et al. [17] also found a higher sodium excretion in connection with BNP infusion, but the difference from placebo was not significant. Another study of the effects of BNP infusion in CHF, by Hobbs et al. [16] , did not determine natriuretic or diuretic parameters. Whether the renal effects of BNP in CHF are different from the effects of ANP is not known.
The purpose of the present study was to measure the effect of a continuous infusion of BNP, 2 pmol:min −" :kg −" , for 60 min in patients with CHF New York Heart Association (NYHA) class II-III and in normal healthy subjects. The primary effect parameters were the urinary sodium excretion and the fractional excretion of sodium. The secondary effect parameters were the urinary flow rate, the urinary potassium excretion, glomerular filtration rate (GFR), renal plasma flow (RPF), filtration fraction, segmental tubular function determined by use of lithium clearance, plasma concentrations of ANP, BNP, renin, angiotensin II, aldosterone, arginine vasopressin and cGMP, and the urinary excretion rate of cGMP, blood pressure and heart rate.
MATERIAL AND METHODS

Study subjects
In the patients with CHF the inclusion criteria were : (i) age between 20 and 65 years ; (ii) both men and women ; (iii) congestive heart failure NYHA class II-III based on clinical examination. In addition, echocardiography and cardiac angiography with measurements of ejection fraction and left ventricular end-diastolic pressure were determined in all patients as a routine diagnostic procedure. The exclusion criteria were : (i) a history of primary disease in the liver, kidneys, lungs or endocrine organs, cerebrovascular insult, neoplasm, hypertension or urinary bladder dysfunction with incomplete emptying ; (ii) cardiac disease with stenosis of the valves ; (iii) ventricular arrhythmias ; (iv) medical treatment with an angiotensin-converting enzyme inhibitor, that could not be discontinued for a week before the examination ; (v) alcohol abuse, defined as more than 21 drinks per week for men and 14 drinks for women.
In the healthy control subjects the inclusion criteria were : (i) age between 20 and 65 years ; (ii) both men and women. The exclusion criteria were : (i) as point one and five for CHF ; (ii) any history of heart disease ; (iii) ongoing medical treatment.
In both groups the withdrawal criteria during the study were : (i) the development of exclusion criteria ; (ii) incomplete emptying of the bladder, i.e. a difference of more than 15 % between the two baseline clearance periods ; (iii) adverse reactions necessitating discontinuation of the study ; (iv) poor compliance. All subjects underwent a medical examination including blood samples for general biochemical and haematological screening (haemoglobin, sedimentation rate, leucocyte count including a differential count, platelet count, plasma sodium, plasma potassium, plasma creatinine, plasma albumin, plasma glucose, plasma alanine aminotransferase, plasma alkaline phosphatase and plasma bilirubin) and urinary screening (albumin, glucose, haemoglobin, nitrite). An ECG was also recorded.
The study was carried out in accordance with the Declaration of Helsinki of the World Medical Association, and informed consent was obtained according to the regulations of the local Medical Ethics Committee.
Nine patients with CHF and 10 healthy control subjects were included in the study. The clinical data for the study subjects are given in Table 1 . None of the subjects was excluded from the study. The 24-h urinary sodium excretion was significantly lower in the CHF group, but otherwise the control subjects and the patients with CHF did not differ regarding the clinical data ( Table  1) .
The CHF was caused by ischaemic heart disease in two patients and by dilated cardiomyopathy in seven patients. Five patients were in NYHA class II and four in class III. The left ventricular ejection fraction determined by echocardiography and cardiac angiography was 20-35 %. All patients had sinus rhythm at the time of the study. A full list of the patients' medication was made. All patients were treated with an angiotensin-converting enzyme inhibitor before inclusion and the drug was discontinued 1 week before the study. All patients were treated with diuretic drugs, seven patients with potassium chloride, six patients with digoxin, two patients with low-dose acetylsalicylic acid and five patients with coumarin or a derivative of coumarin.
Procedure
All subjects were on an unrestricted diet. The day before the study a 24-h urine was collected to evaluate the urinary sodium and potassium excretion. For the CHF group the diuretic treatment was temporarily stopped on the morning of the day of study. The subjects attended the laboratory in the morning at 08 : 00 hours after abstaining from food and water for 8 h before the start, but received 200 ml of water at 30 min intervals from 07 : 00 hours to the end of the study to maintain constant urine production. At 22 : 00 hours the day before the study the subjects were given 300 mg of lithium carbonate orally. Voiding took place in the sitting or standing position ; otherwise the subjects were in the supine position during the examination. Two catheters, one in each arm, were inserted for administration of the tracers, infusion and blood sampling. At 09 : 00 hours a priming dose of &"Cr-EDTA and "#&I-hippuran was given intravenously followed by a continuous infusion to the end of the study. Allowing 1 h for equilibration, urine was collected for six consecutive clearance periods of 30 min each from 10 : 00 to 13 : 00 hours. BNP (Clinalfa, La$ ufelfingen, Switzerland), 2 pmol:min −" :kg −" , was given as a continuous infusion in a 30 ml isotonic sodium chloride solution from 11 : 00 to 12 : 00 hours. For the calculations the mean of two consecutive 30-min periods was used, i.e. one pre-infusion period, one BNP infusion period and one post-infusion period.
For each clearance period the urine was analysed for &"Cr-EDTA, "#&I-hippuran, sodium, potassium, lithium and cGMP, and at the beginning and end of each period venous blood samples were collected for determination of serum &"Cr-EDTA, "#&I-hippuran, sodium, potassium and lithium, and haematocrit. ANP, renin, angiotensin II, aldosterone, arginine vasopressin and cGMP were measured before the start of infusion, at the end of infusion and 60 min after the end of infusion. BNP was measured immediately before the start of infusion, and after 30 and 60 min of infusion, i.e. immediately before termination of infusion, and in addition 5, 10, 20, 30 and 60 min after the termination of infusion. After each blood sample was drawn an equal volume of isotonic sodium chloride was given intravenously. Blood pressure and heart rate were measured twice at the beginning and end of each 30-min clearance period.
Methods
The continuous infusion technique was used for determination of GFR and RPF. GFR was determined as the &"Cr-EDTA clearance and RPF as the "#&I-hippuran
clearance [18] . The filtration fraction was calculated as GFR\RPFi100. Lithium was determined by atomic absorption spectrophotometry and sodium, potassium and haematocrit by conventional methods at the Department of Clinical Biochemistry, Skejby Hospital.
Segmental tubular function was determined by use of the lithium clearance technique [19, 20] , which assumes that lithium is reabsorbed in the proximal tubule to the same extent as sodium and water and that lithium is neither secreted nor reabsorbed in the distal nephron. Thus, lithium clearance (C Li ) equals the output of isotonic fluid from the proximal tubule. With the use of GFR, C Li , clearance of sodium (C Na ) and concentration of sodium in plasma (P Na ), the following parameters could be calculated :
Proximal absolute reabsorption of sodium (PAR Na )
Distal absolute reabsorption of sodium (DAR Na ) l (C Li kC Na )iP Na Distal fractional reabsorption of sodium (DFR Na ) l (C Li kC Na )\C Li i100 GFR, RPF, C Li and the derived parameters were standardized to a body surface of 1.73 m#.
BNP was determined by radioimmunoassay (RIA) [21] . BNP was extracted from plasma using Sep-Pak C-18 cartridges (Waters Associates) activated with methanol and acetic acid. Plasma was applied, followed by washing in acetic acid, elution with ethanol in acetic acid and drying in a Speed Vac evaporator. The antibody in the RIA was raised in rabbits in our laboratory, and the tracer was "#&I-Tyr-BNP. The separation of free and bound tracer was performed by a polyethylene glycol method. There was no cross-reactivity with ANP. The intra-assay coefficient of variation for analysis of BNP was 6.0 % and the inter-assay coefficient was 11.0 %. The lower detection limit was 0.6 pmol\l.
ANP was determined by RIA as described previously [22] . In brief, ANP was extracted from plasma by SepPak C-18 cartridges using ethanol, acetic acid and water. For RIA an ANP antibody raised in rabbits was obtained from the Department of Clinical Biochemistry, Bispebjerg Hospital, Copenhagen, Denmark. The lower detection limit was 0.5 pmol\l plasma, and the intra-and inter-assay coefficients of variation were 10 % and 12 % respectively. There was no cross-reactivity with BNP.
Angiotensin II was determined by RIA using a modification of a method described previously [23] . RIA was performed after extraction from plasma by Sep-Pak C-18 cartridges using methanol and water. Antibody against angiotensin II was raised in rabbits and obtained from the Department of Clinical Physiology, Glostrup Hospital, Copenhagen, Denmark. The lower detection level was 2 pmol\l plasma. The intra-and inter-assay coefficients of variation were 8 % and 12 % respectively.
Aldosterone was measured by a modified RIA method described previously [24] . Aldosterone was extracted from plasma by Sep-Pak C-18 cartridges using trifluoroacetic acid, methanol and water. The aldosterone antibody raised in rabbits was purchased from Biogenesis (Simoco, Denmark). The lower detection limit was 42 pmol\l. The intra-and inter-assay coefficients of variation were 9 % and 13 % respectively.
Arginine vasopressin was measured by a modification of a method described previously [25] . Arginine vasopressin was extracted from plasma by Sep-Pak C-18 cartridges using trifluoroacetic acid, methanol and water. The RIA was performed using an antibody raised in rabbits provided as a gift by Jacques Du$ rr, Department of Medicine, V.A. Center, Bay Pines, FL, U.S.A. The lower detection limit was 0.5 pmol\l. The intra-assay variation was 9 % and the inter-assay variation 13 %.
Renin and cyclic GMP in plasma and urine were measured by commercial RIA kits (Amersham International, U.K., and Nichols Institute, Switzerland). For cGMP the intra-and inter-assay coefficients of variation were 6 % and 9 % respectively, and for renin 2.5 % and 7.4 % respectively.
Blood pressure and heart rate were measured by automatic equipment (Takeda, Japan). At each examination the blood pressure was measured against a Hawkley random zero sphygmomanometer. The mean arterial blood pressure was calculated as the diastolic pressure plus one-third of the pulse pressure (systolic pressure minus diastolic pressure).
Statistics
Non-parametric tests were used for the statistical evaluation. Friedman's test was used for the multiple paired comparison within groups and Mann-Whitney's test for the single, unpaired comparison between groups. Association between two variables was evaluated by calculating the Spearman's rank correlation coefficient. A Pvalue of 0.05 was considered statistically significant. Results are given as median values with ranges in parentheses except when stated otherwise.
RESULTS
Urinary excretion of sodium and the fractional excretion of sodium
The urinary excretion of sodium (U Na V) is given in Figure 1 and the fractional excretion of sodium (FE Na ) in Table 2 . The baseline U Na V and FE Na were significantly The columns in the first period indicate the baseline values. Subsequent columns represent the infusion and post-infusion control periods respectively. Box plot with medians, first and third quartiles and 10th and 90th centiles. *P 0.05. lower in CHF patients than in control subjects (U Na V : 52 µmol\min versus 235 µmol\min, P 0.05 ; FE Na : 0.5 % versus 2.0 %, P 0.05). During BNP infusion, U Na V and FE Na increased significantly in CHF patients (U Na V : 52 to 76 µmol\min, P 0.05 ; FE Na : 0.5 to 0.7 %, P 0.05) and in control subjects (U Na V : 235 to 440 µmol\min, P 0.05 ; FE Na : 2.0 to 3.2 %, P 0.05). Figure 2 shows that during infusion the absolute increase in U Na V was significantly lower (P 0.05) in CHF patients than in control subjects (dU Na V : 27 µmol\min versus 190 µmol\min). The absolute increase in FE Na was also significantly (P 0.05) lower in CHF patients than in control subjects (dFE Na : 0.2 % versus 1.2 %). However, the relative increase in U Na V was not significantly different between the two groups during infusion (CHF, 60 % ; control, 71 %), and neither was the relative increase in FE Na (CHF, 62 % ; control, 68 %).
There was no correlation between the 24-h urinary sodium excretion and the urinary sodium excretion in the three 1-h periods, in either control subjects or CHF patients.
Urinary flow rate
The urinary flow rate (V) is given in Figure 1 . The baseline V was significantly lower in CHF patients than in control subjects (5.1 ml\min versus 7.7 ml\min, P 0.05), but did not change significantly during BNP infusion in either group. Box plot with medians, first and third quartiles and 10th and 90th centiles. *P 0.05.
Urinary excretion of potassium
Urinary excretion of potassium (U K V) is given in Figure  1 . The baseline U K V did not differ significantly between CHF and control subjects. The U K V decreased in both groups in the post-infusion period, but the relative decrease was not significantly different between the two groups (control, k63 % ; CHF, k52 %).
Glomerular filtration rate, renal plasma flow and filtration fraction
Glomerular filtration rate, renal plasma flow and filtration fraction are given in Table 2 . The baseline values for GFR and RPF were reduced significantly in CHF patients, but the filtration fraction values did not differ between the two groups. No significant changes were found for GFR and RPF in CHF patients, whereas GFR increased during BNP infusion and RPF decreased in the post-infusion period in control subjects. Filtration fraction was increased during and after BNP infusion in CHF patients and after the infusion in control subjects. However, neither the absolute nor the relative changes in GFR, RPF and filtration fraction were significantly different between the control subjects and the CHF group.
Lithium clearance
Lithium clearance (C Li ), fractional excretion of lithium (FE Li ) and the derived sodium handling parameters, the proximal absolute reabsorption (PAR Na ), the proximal fractional reabsorption (PFR Na ), the distal absolute reabsorption (DAR Na ) and the distal fractional reabsorption (DFR Na ) are given in Table 2 .
Baseline values for lithium clearance and fractional excretion of lithium were normal in CHF patients. Lithium clearance increased significantly (17 %) during infusion in control subjects. The fractional excretion of lithium did not change significantly in either group, and the relative changes in lithium clearance and fractional excretion of lithium were not significantly different between the two groups in any of the periods.
In CHF patients the basal value of the proximal absolute reabsorption of sodium was reduced (CHF, 7.5 mmol:min −" :1.73 m −# ; control, 9.3 mmol:min −" : 1.73 m −# , P 0.05), and the distal fractional reabsorption of sodium was increased (CHF, 98 % ; control, 94 %, P 0.05). Proximal absolute reabsorption declined in the post-infusion period in the CHF group, and no changes were recorded in the control group, but the relative changes did not differ between the two groups. BNP infusion did not induce any significant changes in the proximal fractional or distal absolute reabsorption of sodium in either group. The distal fractional reabsorption of sodium decreased during and after BNP infusion in both groups (see Table 2 ). The absolute decrease in distal fractional reabsorption of sodium (Figure 2 ) was significantly lower (P 0.05) during BNP infusion in CHF patients than in the control subjects (dDFR Na : k0.8 % versus k3.4 %). Also, the relative decrease was significantly lower (P 0.05) during infusion in the CHF group (DFR Na : k0.8 % versus k3.7 %). 
BNP and cGMP
Plasma BNP is given in Figure 3 . The baseline value for CHF patients [25 (1.0-65) pmol\l] was significantly (P 0.05) elevated compared with control subjects [1.6 (0.8-3.1) pmol\l]. In CHF patients the level varied considerably. The peak values at the end of infusion were 101 pmol\l and 173 pmol\l for control subjects and CHF patients respectively. BNP was still above pre-infusion levels 60 min after termination of the infusion (control, 9.9 pmol\l ; CHF, 35 pmol\l). The ratio of BNP to baseline BNP was at all times during and after the BNP infusion significantly lower in CHF patients than in Table 3 Concentration in plasma of cGMP and urinary excretion of cGMP in three consecutive 60-min clearance periods in healthy subjects (control) and patients with congestive heart failure (CHF) BNP, 2 pmol:min − 1 :kg − 1 , was infused in the second period during the 60 min. Values are given as medians with ranges and the relative changes as a percentage in parentheses. Comparison of baseline value (before infusion or period 1) and the consecutive measurements of cGMP in plasma and urinary excretion of cGMP respectively within groups : *P 0.05.
Before infusion
At termination of infusion 60 min after termination of infusion control subjects. In control subjects the ratio increased maximally 71-fold (33-106-fold) and in CHF patients it increased 7-fold (3-69-fold).
The effect of BNP infusion on plasma cGMP and urinary excretion of cGMP is given in Table 3 . The baseline plasma cGMP and urinary excretion of cGMP were significantly elevated in CHF patients compared with control subjects. Plasma cGMP increased during BNP infusion and declined 60 min after termination of infusion to pre-infusion levels in both groups, whereas the urinary excretion of cGMP was increased during and after the infusion. The absolute increases were equal in the two groups in both plasma and urine, but the relative increase in plasma cGMP immediately after the infusion was lowest in CHF (58 % compared with 98 % in control subjects, P 0.05).
Plasma cGMP and plasma BNP, urinary excretion of cGMP and plasma BNP or the absolute or relative changes in these parameters did not show any relationship before, during or after the BNP infusion. However, the ratio between plasma cGMP and plasma BNP and the ratio between urinary excretion of cGMP and plasma BNP were significantly lower (P 0.05) in CHF patients before and after, but not during, the BNP infusion. The ratios between the absolute or relative changes in these parameters did not differ.
ANP, renin, angiotensin II, aldosterone and arginine vasopressin
Plasma concentrations of ANP, renin, angiotensin II, aldosterone and arginine vasopressin are given in Table 4 . The baseline values for ANP and renin were significantly elevated in CHF patients, whereas values for angiotensin II, aldosterone and arginine vasopressin were all normal, although tended to be higher in CHF patients than in control subjects. ANP increased significantly at the termination of infusion in both groups. In control subjects, ANP declined insignificantly 60 min after termination of infusion, but was unaltered in the CHF group. The relative change in ANP 60 min after termination of infusion was significantly smaller in CHF patients compared with control subjects (0 % and k24 % respectively).
Renin decreased significantly in both groups 60 min after termination of infusion, but the relative decreases were similar in the CHF patients and control subjects.
No significant absolute changes were induced in angiotensin II within groups, but in CHF patients a slight but significant relative decrease was seen both at termination of the infusion (CHF, k17 % ; control, 0 %) and 60 min later (CHF, k22 % ; control, 17 %).
BNP infusion did not affect aldosterone or arginine vasopressin significantly.
Haematocrit
The haematocrit was measured before BNP infusion . In CHF patients the haematocrit decreased significantly both at termination of the infusion (k2.6 %) and 60 min later (k2.8 %), whereas a slight but non-significant increase (0.0 % and 1.1 %) was seen in control subjects.
Blood pressure and heart rate
The mean arterial blood pressure was determined before, during and after each 1-h period (meanpS.D.) : [CHF, 90p9 mmHg, 87p8 mmHg, 90p7 mmHg, 95p 11 mmHg, 101p10 mmHg, 90p8 mmHg, 87p7 mmHg; control, 90p10 mmHg, 90p11 mmHg, 93p8 mmHg, 96p9 mmHg, 96p8 mmHg, 92p10 mmHg, 91p 9 mmHg]. The mean arterial blood pressure was significantly elevated in CHF patients in the middle (j10 %) and at the end of BNP infusion (j10 %), and in control subjects at the end of infusion (j7 %), but no significant differences were seen between the groups.
The heart rate was measured in a similar manner to the blood pressure. CHF : 66p14, 62p13, 63p12, 61p14, 62p15, 61p14, 69p10 and control : 57p13, 57p10, 60p10, 57p10, 56p10, 57p11, 60p12. The heart rate did not change significantly.
DISCUSSION
Chronic CHF is a common syndrome and is still associated with high morbidity and mortality in spite of improved medical treatment in recent years. Cardiac dysfunction is accompanied by activation of vasoconstrictor and sodium-and water-retaining factors, i.e. the renin-angiotensin-aldosterone system, vasopressin and the sympathetic adrenergic system [1, 2] . Today, the medical treatment of CHF aims to inhibit these factors [26, 27] . The natriuretic peptides ANP and BNP have been found to be elevated concurrently with the vasoconstrictor factors [3, 4] . The purpose of the present study was primarily to measure and to compare the renal effects of BNP infusion in patients with CHF and healthy control subjects. The dose of BNP used was chosen in accordance with our results in a previous study in younger, healthy subjects in a similar setting, where the infusion of 2 pmol:min −" :kg −" increased the urinary sodium excretion by 88 % during infusion [28] . The natriuretic effect of BNP did not increase further by doubling the dose to 4 pmol:min −" :kg −" .
The increments in plasma BNP during the infusion are unexpectedly high as assessed by reference to previous studies of both healthy subjects and patients with heart failure [10, 11, 17] , whereas the levels before infusion are in good agreement with the literature. Measurement of BNP by different RIA methods must be the explanation [21] .
The effect of a continuous BNP infusion was an impaired natriuretic response in patients with chronic heart failure compared with healthy subjects. The urinary sodium excretion and the fractional excretion of sodium increased significantly in both CHF patients and control subjects, but the relative increases were not significantly different between the two groups. However, the absolute increases in urinary sodium excretion and fractional sodium excretion were significantly lower in CHF patients. The absolute increases were 5-6-fold higher in the healthy subjects. Urinary flow rate was unchanged.
The response to ANP infusion is known to depend on sodium intake [29] , which must also be the case for BNP. The 24-h urinary sodium excretion was significantly lower in the patients but still within the normal range of the general population, and thus also within the limits found in our previous study in younger, healthy subjects [28] . We did not use a sodium diet as in the study by Lainchbury et al. [17] , who used a constant sodium diet giving a 24-h sodium excretion of 80-82 mmol. This study found a higher, but not significantly higher, sodium excretion in connection with BNP infusion compared with placebo. In the present study, no correlation was found between the 24-h urinary sodium excretion and the urinary sodium excretion in control subjects or in CHF patients. Apart from the withdrawal of the angiotensin-converting enzyme inhibitor 1 week before the examination, the diuretic treatment and other medication continued unchanged until the study day and the dose of the diuretic drugs had been stable for at least 2 weeks. On the study day the patients were well compensated, had a normal plasma sodium and the haematocrit did not differ significantly from the healthy subjects at the start of the study. Thus, it does not seem likely that the attenuated natriuretic response in CHF patients is due to sodium or volume depletion. Still, the baseline urinary sodium excretion and the fractional excretion of sodium were significantly decreased in CHF patients. The temporary discontinuation of the diuretic medication on the study day may lead to a tendency to retain sodium, but on the other hand, the diuretic treatment may have such a long biological half-life that the natriuretic and diuretic effects still persisted on the study day. Ideally, the study should have been performed in untreated patients, also including a placebo treatment study day. This was not possible for a number of reasons including ethical precautions and the study performed was therefore a compromise. The decreased sodium excretion in CHF patients is probably due to one of the genuine pathophysiological mechanisms in CHF.
A similar natriuretic effect of BNP in CHF was found by Marcus et al. [15] where mainly the haemodynamic effects of incremental infusions of BNP were investigated in the range 1-30 pmol:min −" :kg −" . This study found a doubling of natriuresis and an improvement of diuresis by approximately one-third. Lainchbury et al. [17] , as mentioned above, also found a higher sodium excretion during BNP infusion, but the difference from placebo was not significant. Yoshimura et al. [14] found a 5-fold increase in diuresis and nearly a 10-fold increase in urinary sodium excretion when infusing approximately 30 pmol:min −" :kg −" for 30 min. The natriuretic effect was even greater in the patients with CHF than in the control subjects. The differences in design, severity of the heart disease, concurrent medications, doses of BNP, daily sodium intake and time spans may explain the discrepancies between the studies.
The mechanism of the increase in natriuresis may involve an increase in GFR and\or a decrease in tubular reabsorption of sodium. GFR did not change significantly in the patients with CHF, whereas BNP produced an increase in GFR in the healthy subjects. However, the relative changes did not differ between the two groups. Thus, BNP probably has its main effect on the renal tubules.
The effect of BNP on segmental tubular function was determined by use of the lithium clearance technique. This method is still controversial but, in general, the application of the method is accepted and is reliable in humans on a normal or high sodium diet [19, 20] . Data concerning a possible effect of BNP on lithium absorption in the loop of Henle are not available, but receptors for the natriuretic peptides have not been found in this segment. Application of the method is based on the assumption that lithium is only reabsorbed in the proximal part of the nephron and that lithium is reabsorbed to the same extent as sodium and water [18, 19] . The above mentioned reservations concerning the temporary discontinuation of the diuretic medication on the study day, and a possible late effect due to a long biological half-time of the diuretic drugs, must also be considered when applying the lithium clearance method in this setting. Acute diuretic treatment increases the lithium clearance in healthy subjects [19] , but this has never been investigated in patients with CHF. One would expect the diuretic treatment before the study day to have an increasing effect, if any. As the baseline sodium excretion on the study day was much lower in the CHF patients than in the healthy subjects and as a calculated median 24-h sodium excretion based on this baseline sodium excretion (75 mmol\24 h) was lower than the collected median 24-h sodium excretion the day before the study, we made the assumption that the previous diuretic treatment had no major influence on the lithium clearance on the study day.
BNP seems not to have any effect on the proximal tubule, as the fractional excretion of lithium did not change significantly in either group. The distal fractional reabsorption of sodium decreased in CHF patients and healthy subjects but the relative decrease was significantly lower in the former. Thus, the impaired natriuretic response in patients with CHF is probably caused by abnormal sodium handling in the distal part of the nephron. In other words, the high distal fractional reabsorption of sodium in CHF seems to be refractory to the BNP infusion. Previous studies in humans have located receptors for BNP in the kidneys [30, 31] , and studies in animals have found discrete binding sites in the inner medulla and also in the glomeruli [32] [33] [34] [35] . The infusion increased the BNP level to a greater extent in CHF patients than in healthy subjects, but owing to the chronically elevated plasma level in patients, the relative increase was 7-fold in the patients compared with 71-fold in the healthy subjects. BNP induced the same absolute increase in cGMP in the two groups in both plasma and urine, but the relative increase in plasma cGMP immediately after the infusion, the ratio of plasma cGMP to plasma BNP, and the ratio of urinary excretion of cGMP to plasma BNP were significantly lower (before and after infusion) in CHF patients. It is likely that the changes in the cGMP response play a role in the impaired natriuretic effect of BNP in CHF. The chronic elevation of the natriuretic peptides seen in heart failure might lead to a modification of the natriuretic response owing to several mechanisms : down-regulation of the receptors (NPR-A), reduction of the secondary messenger response (cGMP), reduction of the response to the secondary messenger (post-receptor uncoupling) and counter-regulating mechanisms due to activation of antinatriuretic hormones and regulators. Renin in plasma was elevated in CHF and decreased significantly in CHF patients as well as in control subjects, but the relative decreases were similar in the two groups. Aldosterone in plasma was unaffected by the BNP infusion. The study by Yoshimura et al. [14] found a suppression of aldosterone in both patients and control subjects, and it is generally accepted that natriuretic peptides have an antagonistic effect on aldosterone.
The increase in ANP during BNP infusion could be explained by saturation of the metabolic pathways [neutral endopeptidase and the clearance receptor (NPR-C)] due to the higher level of BNP present during infusion [11, 14, 36] . The lower ANP level in control subjects at termination of the study may represent a reduced stimulus for the release of ANP from the atria due to a reduction of the intravascular volume caused by a greater diuresis and haemo-concentration in this group. The declining haematocrit in CHF might in part be explained by an impaired ability of BNP to increase the vascular permeability in CHF.
Quite unexpectedly we found that the mean arterial blood pressure increased slightly in the patients with CHF and in the healthy subjects during the BNP infusion. The reason for this phenomenon is unknown ; it may simply reflect the conditions of the study.
It is concluded that infusion of BNP induced natriuresis in patients with CHF, but the natriuretic effect was impaired compared with healthy subjects. A moderated cGMP response may take part in the attenuated natriuretic effect. It is likely that the impaired natriuretic response was caused by a reduced responsiveness in the distal part of the nephron.
